FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Check this box if no longer subject	
to Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Sebaaly Camille					2. Issuer Name and Ticker or Trading Symbol Sunshine Biopharma, Inc [SBFM]										k all app Direc	tionship of Reportir all applicable) Director Officer (give title below) CFO/S		10% O	wner
(Last) (First) (Middle) 14464 GOUIN W.					3. Date of Earliest Transaction (Month/Day/Year) 06/03/2022									X				below)	specify
(Street) MONTREAL A8 H9H 1B 					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Ind Line) X					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date				Date	e Exe nth/Day/Year) if a			A. Deemed Execution Date, f any Month/Day/Year)		3. Transaction Code (Instr. 8) 4. Securitie Disposed (5)				4 and Secur Bene		cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount	(A) o (D)	^r Pr	ice	Transa	ction(s) 3 and 4)			(11311. 4)
Common Stock				06/03/2022					Р		25,000	A	\$	1.22 1		4,465		D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date ecurity or Exercise (Month/Day/Year)		3A. Deeme Execution if any (Month/Da	ion Date, Day/Year) Transacti Code (Ins 8)		Instr.			6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration		7. Title and Amount of Securities Underlying Derivative Security (Insi 3 and 4) Amoun or Numb of Title Share:		nt er		9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	

Explanation of Responses:

/s/ Camille Sebaaly

** Signature of Reporting Person Date

06/06/2022

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.